All News

Explore how ADCs reshape breast cancer care, with practical sequencing strategies across subtypes and guideline-based toxicity management for ILD, neutropenia, and GI effects.

Real-world data show most first-line mTNBC patients are immunotherapy-ineligible, use chemotherapy, and face poorer survival, underscoring major unmet treatment needs.

The addition of epcoritamab to lenalidomide and rituximab showed improved efficacy and manageable safety in relapsed/refractory follicular lymphoma.

Data from the CASSIOPEIA trial showed that more than half of patients with high-risk disease achieved 5-year disease-free survival with tisagenlecleucel.

Adverse drug reactions occurred in 1 patient treated with VT-EBV-N, although no grade 3 or higher events emerged.

Phase 3 results support anbenitamab plus albumin-bound docetaxel as a new treatment option in HER2-positive breast cancer across disease stages.

Experts discuss how updated findings from the TALAPRO-3 and PROTEUS trials may impact the prostate cancer paradigm.

T-DXd demonstrated a real-world overall response rate of 56.3%, median rwPFS of 7.4 months, and 12-month OS of 62% in patients with HER2-low metastatic breast cancer treated across US community oncology settings.

In a real-world cohort of 300 patients with HER2-low metastatic breast cancer, T-DXd demonstrated a safety profile consistent with DESTINY-Breast04 in community oncology settings, with ILD/pneumonitis in 10% and toxicity-related discontinuation in 15%.

Updated data from the ASC4FIRST trial affirm asciminib as the treatment of choice for many patients with chronic myeloid leukemia in chronic phase.

A recommendation from the external data monitoring committee led to the discontinuation of the phase 3 KEYNOTE D46/EVOKE-03 study.

Karen Reckamp, MD, MS, analyzed the shifting funding models in academic oncology and the necessity of philanthropy to support clinical trial infrastructure.

Zovegalisib plus fulvestrant demonstrated an objective response rate of 38.7% and a median progression-free survival of 10.3 months in PIK3CA-mutant HR+/HER2– advanced breast cancer in the ReDiscover trial.

ctDNA-based next-generation sequencing in 236 patients with advanced breast cancer revealed frequent PIK3CA, TP53, and ESR1 mutations, highlighting key mechanisms of endocrine resistance with implications for targeted therapy selection.

The clearance enables the developers to include China-based centers in an ongoing phase 1a/1b trial evaluating the agent in late-stage solid tumors.

Daraxonrasib plus vopimetostat demonstrated a favorable RAS-associated safety profile in patients with MTAP-deleted, pretreated metastatic pancreatic ductal adenocarcinoma.

Sarah Weiss, MD, highlights pivotal updates in uveal melanoma, intratumoral neoadjuvant therapy, and Merkel cell carcinoma from the 2026 ASCO Annual Meeting.

Higher ACE counts were significantly associated with greater symptom burden during anti-estrogen therapy in patients with stage I to IV breast cancer in the Appalachian region of Tennessee.

Dato-DXd plus durvalumab demonstrated robust antitumor activity as first-line treatment for advanced/metastatic triple-negative breast cancer in the phase 1b/2 BEGONIA study, with manageable safety.

Although the results from persevERA were not statistically significant, they may support using oral SERDs for patients with ER+/HER2– breast cancer.

The approval of the on-body injector in multiple myeloma follows a positive opinion from the EMA’s Committee for Medicinal Products for Human Use.

Considering the toxicity burden of dual checkpoint inhibition for adjuvant RCC, Saum Ghodoussipour, MD, posited potential alternatives in the space.

Experts discuss abstracts from the 2026 ASCO Annual Meeting that may represent critical advances across multiple myeloma, leukemia, and lymphoma.

A phase 1/1b first-in-human study is evaluating the CNS-penetrant selective ERBB2 inhibitor CGT4255 across multiple tumor types, including HER2-positive breast cancer with brain metastases.

A dual-perspective survey of patients and physicians with metastatic breast cancer identified financial, logistical, and trust-related barriers to trial participation, with greater burden among racial and ethnic minorities.

Saum Ghodoussipour, MD, provided an in-depth analysis of the RAMPART readout, exploring the DFS benefit of a durvalumab/tremelimumab combination in RCC.

Among US women aged 65 and older, foreign-born individuals showed higher self-reported breast cancer prevalence than US-born women, challenging assumptions from studies of younger populations.

Extended drug cessation appears feasible in exceptional responders with HER2+ de novo metastatic breast cancer, with significantly better survival compared with non-exceptional responders.

The safe administration of revumenib among pediatric patients broadens the applicability of results seen with the menin inhibitor.

Catch up on major clinical trials reshaping treatment for brain metastases, Merkel cell carcinoma, cervical cancer, and head and neck cancer, all from ASCO 2026.